Getting into the biosimilars action

In March 2016, the Federal Trade Commission (FTC) filed a suit against Endo Pharmaceuticals (among others) for blocking generic competition of its Opana ER (oxymorphone hydrochloride) and Lidoderm (lidocaine) products. It alleged that in addition to paying to delay competitive products, Endo used a no-AG (authorised generic) commitment that gave Watson Laboratories more than seven months of its own monopoly on the market during which Endo would not compete.